Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2018-03-29 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
关于2015年非公开发行股票募集资金项目中收购北京华方科泰100%股权所涉业绩承诺实现情况的说明及致歉公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Kunming Pharmaceutical Group Co., Ltd. regarding the performance commitment related to the 2015 non-public issuance of shares used to acquire 100% equity of Beijing Huafang Ketai. It details the performance targets, actual results, reasons for underperformance, compensation commitments, and an apology statement. The document references a special audit report but does not contain full financial statements or comprehensive financial data itself. It is a disclosure about a specific transaction's performance and related compensation, not a full annual report, audit report, or interim report. The document length is relatively short (2685 characters) and it is a formal announcement of performance results and compensation related to a capital raising and acquisition transaction. This fits best under Capital/Financing Update (CAP) as it relates to fundraising and use of proceeds with performance commitments and compensation disclosures.
2018-03-29 Chinese
子公司昆药集团医药商业有限公司关于曲靖市康桥医药有限责任公司、楚雄州虹成药业有限公司、大理辉睿药业有限公司未完成业绩承诺或情况的专项审核报告
Regulatory Filings Classification · 95% confidence The document is a detailed explanation regarding the performance commitments and compensations related to subsidiaries of Kunming Pharmaceutical Group Co., Ltd. It references specific financial performance targets, audit results by a CPA firm, and discusses reasons for underperformance and planned corrective measures. The document is not a full annual or interim report but rather a specific disclosure related to asset restructuring and performance guarantees under regulatory requirements (citing the China Securities Regulatory Commission's rules). It includes detailed financial figures and audit confirmations but is focused on performance commitments and compensations related to acquisitions. This type of document aligns with disclosures related to major asset restructuring and performance guarantee explanations, which typically fall under Regulatory Filings (RNS) as it does not constitute a full financial report or standalone audit report but a regulatory disclosure about asset restructuring and performance commitments.
2018-03-29 Chinese
关于昆药集团医药商业有限公司部分并购标的公司未达到业绩承诺的情况说明公告
M&A Activity Classification · 95% confidence The document is a public announcement by Kunming Pharmaceutical Group Co., Ltd. regarding the performance shortfall of certain acquisition targets of its subsidiary Kunming Pharmaceutical Commercial Co., Ltd. It details the acquisition transactions, performance commitments, actual performance results audited by an accounting firm, reasons for underperformance, and proposed remedial measures. The document is an announcement explaining the status of performance commitments related to mergers and acquisitions, not a full financial report or audit report. It does not contain comprehensive financial statements or detailed audit opinions but rather a disclosure about M&A-related performance issues and compensation arrangements. Therefore, it fits best under the category of M&A Activity (TAR), which covers announcements and documents related to merger proposals or takeover bids and related performance disclosures.
2018-03-29 Chinese
监事会关于公司会计政策变更的审核意见
Audit Report / Information Classification · 90% confidence The document is a supervisory board's audit opinion on a change in accounting policies of the company. It is a short statement expressing approval and compliance with regulations, without detailed financial data or full audit report content. It is not a full audit report or annual report but an audit opinion related to accounting policy changes. Given the short length and nature, it fits best under Audit Report / Information (AR) category, which includes standalone audit reports and applied accounting principles. FY 2017
2018-03-29 Chinese
董事会关于公司会计政策变更的说明
Regulatory Filings Classification · 95% confidence The document is a statement from the company's board regarding a change in accounting policies. It references specific accounting standards and confirms that the change does not affect financial results. The document is short (375 characters) and serves as an announcement or explanation rather than a full financial report or audit. It does not contain financial statements or detailed analysis. Therefore, it is best classified as a Regulatory Filing (RNS), which covers miscellaneous regulatory announcements that do not fit other categories.
2018-03-29 Chinese
独立董事对公司对外担保情况的专项说明及独立意见
Audit Report / Information Classification · 95% confidence The document is a special statement and independent opinion by the independent directors of Kunming Pharmaceutical Group Co., Ltd. regarding the company's external guarantees to subsidiaries as of December 31, 2017. It references regulatory notices from the China Securities Regulatory Commission and the Shanghai Stock Exchange related to external guarantees and disclosure requirements. The content is focused on detailed disclosure of guarantee amounts, terms, and compliance with regulations, along with the independent directors' opinion on the legality and appropriateness of these guarantees. This type of document is a standalone audit-related disclosure concerning the company's external guarantee activities, not a full annual report or interim report. It is not a general regulatory filing or announcement but a specific audit-related statement on guarantees. Therefore, it fits best under the category Audit Report / Information (AR). The document length (5223 characters) supports it being a substantive report rather than a brief announcement or certification. FY 2017
2018-03-29 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.